Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov 19;14(1):92.
doi: 10.1186/1129-2377-14-92.

Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?

Hatem S Shehata  1 , Mohamed S El-Tamawy, Nevin M Shalaby, Gihan Ramzy
Affiliations
Randomized Controlled Trial

Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?

Hatem S Shehata et al. J Headache Pain. .

Abstract

Background: Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, mostly by acting on neurogenic inflammatory mediators and controlling the neurotransmitter release of sensory and autonomic nerve terminals that are involved in many chronic painful conditions as chronic intractable trigeminal neuralgia (TN).The aim of our work was evaluating the efficacy, safety, and tolerability of BTX-A for the treatment of intractable idiopathic TN.

Methods: This was a randomized, single-blinded, placebo-control study carried out on 20 Egyptian patients with intractable TN. Patients received a one-time subcutaneous administration of BTX-A using "follow the pain" method. The primary efficacy measure was reduction in pain severity on the 10-cm VAS score as well as in paroxysms frequency from the baseline to week 12 (endpoint last observation carried forward [LOCF]). Secondary efficacy measures included QoL assessment and number of acute medications received from baseline to the endpoint.

Results: Pain reduction at the 12-week endpoint was significant in BTX-A group (p<0.0001); VAS scores at endpoint LOCF relative to baseline for BTX-A group showed a decrease of 6.5 compared with a decrease of 0.3 for placebo, also there was a significant decrease in the number of acute medications and an increase in QoL functioning scale.

Conclusion: These results indicate that BTX-A has a direct analgesic effect in patients with TN and can represent a therapeutic option for intractable cases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Mean scores of VAS during follow up visits.
See this image and copyright information in PMC

References

    1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia. 2004;24(Suppl 1):9–160. - PubMed
    1. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract. 2006;6:153–160. doi: 10.1111/j.1533-2500.2006.00079.x. - DOI - PubMed
    1. Taylor JC, Brauer S, Espir MLE. Long term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J. 1981;57:16–18. doi: 10.1136/pgmj.57.663.16. - DOI - PMC - PubMed
    1. Dalessio DJ. Trigeminal neuralgia. A practical approach to treatment. Drugs. 1982;24(3):248–255. doi: 10.2165/00003495-198224030-00005. - DOI - PubMed
    1. Cruccu G, Truini A. Refractory trigeminal neuralgia. Non-surgical treatment options. CNS Drugs. 2013;27(2):91–96. doi: 10.1007/s40263-012-0023-0. - DOI - PubMed

Publication types

Substances